title: Biosimilar insulin and insulin antibodies.
authors.forename: Lutz
authors.initials: L
authors.lastname: Heinemann
authors.forename: David
authors.initials: D
authors.lastname: Owens
mesh_terms: D057134:Antibodies, Neutralizing / Q000009:adverse effects; D001364:Awareness; D059451:Biosimilar Pharmaceuticals / Q000191:economics / Q000627:therapeutic use*; D017046:Cost Savings; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000191:economics / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D017277:Drug Approval; D057915:Drug Substitution / Q000191:economics; D006801:Humans; D007328:Insulin / Q000031:analogs & derivatives* / Q000191:economics / Q000276:immunology* / Q000627:therapeutic use; D007330:Insulin Antibodies / Q000009:adverse effects* / Q000096:biosynthesis
chemical_list: D057134:Antibodies, Neutralizing; D059451:Biosimilar Pharmaceuticals; D007328:Insulin; D007330:Insulin Antibodies
references.citation: Diabetes Care. 2005 Sep;28(9):2161-9
references.pmid: 16123484
references.citation: Expert Opin Biol Ther. 2012 Aug;12(8):1009-16
references.pmid: 22583127
references.citation: Diabetes Technol Ther. 2012 Nov;14(11):989-96
references.pmid: 23046400